Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific director
Scientific production - Institute for Cancer Research
| Publications | Doctoral theses | |
| 2013 | so far | |
| 2012 | 192 | 18 |
| 2011 | 183 | 22 |
| 2010 | 198 | 11 |
| 2009 | 167 | 21 |
| 2008 | 144 | 11 |
The Institute is engaged in both basic and translational cancer research involving experimental research on model organisms from various evolutionary levels as well as human material from all types of cells and tissues. The co-localisation with a large cancer hospital fulfils the premises for advanced medical research across sciences, a necessity towards the goals of individualised diagnostics and treatment for cancer patients.
Go back
Print this page
E-mail this pageLatest publications
Inst. for Cancer Research
High-Purity Hydrogen via the Sorption-Enhanced Steam Methane Reforming Reaction over a Synthetic CaO-Based Sorbent and a Ni Catalyst
Environ Sci Technol (in press)
PubMed 23675760
Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
PLoS One, 8 (5), e63723
PubMed 23675504
Sustained EKR inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy
Biochim Biophys Acta, 1830 (3), 2659-70
PubMed 23671927
Selected publications
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
High-Purity Hydrogen via the Sorption-Enhanced Steam Methane Reforming Reaction over a Synthetic CaO-Based Sorbent and a Ni Catalyst
Environ Sci Technol (in press)
PubMed 23675760
A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells
FASEB J (in press)
PubMed 23671272
Influence of KIR gene copy number on natural killer cell education
Blood (in press)
PubMed 23637128
